Introduction
Cooperating with Illumina, a global leader in DNA sequencing, the Genomic Core Laboratory of the Precision Medicine Center at Chi Mei Hospital was equipped with the flagship NovaSeq 6000 in March 2022, featuring next-generation liquid biopsy sequencing. With only 2 tubes of blood samples, a 523-gene profiling results can be generated in no more than 10 calendar days, ranking among the world's most efficient laboratory.
Features / strengths
Effective and robust reporting results are enabled by the use of blood samples to eliminate the time spent retrieving tissue samples. With high flexibility and multiplexed solutions being available to analyze blood and tissue samples, timely 523 genomic profiling results facilitate diagnostic assistance and precision medicine for the physicians.
Specification in detail
TSO500 ctDNA
The test is a hybrid capture-based targeted Next-Generation Sequencing assay designed for pan-cancer genomic profiling from plasma specimen. Genomic alteration profiled by this test includes single nucleotide variations in 523 genes, copy number variations in 59, and gene fusions in 23 genes. Tumor mutation burden and microsatellite instability are also determined by sequencing covering 1.94 Mb genome and more than 2400 loci, respectively.
